These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31919773)

  • 1. Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial.
    Abouhussein MA; Gomaa AR
    Int Ophthalmol; 2020 May; 40(5):1147-1154. PubMed ID: 31919773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
    Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept and navigated versus conventional laser in diabetic macular oedema: a 12-month randomized clinical trial.
    Blindbaek SL; Peto T; Grauslund J
    Acta Ophthalmol; 2020 Jun; 98(4):347-352. PubMed ID: 31602811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
    Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
    Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial.
    Blindbaek SL; Peto T; Grauslund J
    Acta Ophthalmol; 2020 Jun; 98(4):353-359. PubMed ID: 31654501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial.
    Kanar HS; Arsan A; Altun A; Akı SF; Hacısalihoglu A
    Indian J Ophthalmol; 2020 Jan; 68(1):145-151. PubMed ID: 31856493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
    Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
    Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema.
    Lai FHP; Chan RPS; Lai ACH; Tsang S; Woo TTY; Lam RF; Yuen CYF
    Jpn J Ophthalmol; 2021 Sep; 65(5):680-688. PubMed ID: 34125326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
    Wykoff CC; Le RT; Khurana RN; Brown DM; Ou WC; Wang R; Clark WL; Boyer DS;
    Am J Ophthalmol; 2017 Jan; 173():56-63. PubMed ID: 27702624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
    Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks.
    Hernández-Bel L; Cervera-Taulet E; Navarro-Palop C; Castro-Navarro V; Chiarri-Toumit C; Montero-Hernández J
    Ophthalmologica; 2019; 241(2):98-104. PubMed ID: 29996128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
    Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.